Overview

DE-117 Spectrum 5 Study

Status:
Recruiting

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost/non-responder subjects diagnosed with POAG or OHT

Phase:

Phase 3

Details

Lead Sponsor:

Santen Inc.

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions